Abbott India Limited has announced its unaudited financial results for the second quarter and half year ended September 30, 2026. The company reported a profit of ₹453.45 crore for the quarter, a notable increase compared to the previous periods. The Board of Directors has approved these results, which also include a limited review report from the statutory auditors. Detailed financial statements, including profit and loss accounts and balance sheets, have been submitted.
Abbott India Announces Q2 FY27 Financial Results
Abbott India Limited has officially released its unaudited financial results for the quarter and half year ended September 30, 2026. These results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on November 5, 2026.
Quarterly Performance Highlights
For the quarter ended September 30, 2026, the company reported a total income of ₹2,019.07 crore. The profit before tax stood at ₹610.47 crore, and after accounting for tax expenses of ₹157.02 crore, the net profit for the quarter was ₹453.45 crore. This performance represents a positive trend for the company.
Half-Yearly Performance
For the six months ended September 30, 2026, Abbott India’s total income reached ₹3,908.12 crore. The profit before tax for this period was ₹1,182.68 crore, with a net profit after tax of ₹881.97 crore. The company also reported total comprehensive income, net of tax, of ₹882.06 crore for the same period.
Balance Sheet Overview
As of September 30, 2026, the company’s total assets stood at ₹5,924.91 crore. Equity and liabilities were also reported, with total equity at ₹4,270.20 crore and total liabilities at ₹1,654.71 crore (comprising non-current liabilities of ₹232.39 crore and current liabilities of ₹1,422.32 crore).
Cash Flow Statement Summary
The statement of cash flows for the six months ended September 30, 2026, indicates net cash generated from operating activities amounted to ₹658.97 crore. Investing activities resulted in net cash flows of ₹1,159.19 crore, while financing activities used net cash of ₹1,423.05 crore. The net increase in cash and cash equivalents for the period was ₹395.11 crore, bringing the closing balance to ₹837.44 crore.
Auditor’s Limited Review
The unaudited financial results have undergone a limited review by the statutory auditors, Walker Chandiok & Co. LLP. The auditors’ report does not contain any qualifications, confirming the adherence to accounting principles and regulatory requirements.
Segment Reporting
The company operates in a single segment, ‘Pharmaceuticals,’ rendering segment-specific disclosures inapplicable.
Source: BSE
